Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

-Ahead of print
-Authors' Accepted
    Manuscripts
new!
-Current Issue
-Archive
-Acknowledgments
-Special Issues
-Browse by Category

Manuscript Submission

-Online Submission
-Online Review
-Instruction for Authors
-Instruction for Reviewers
-English Corner new!

About AJA

-About AJA
-Editorial Board
-Contact Us
-News

Resources & Services

-Advertisement
-Subscription
-Email alert
-Proceedings
-Reprints

Download area

-Copyright licence
-EndNote style file
-Manuscript word template
-Guidance for AJA figures
    preparation (in English)

-Guidance for AJA figures
    preparation (in Chinese)

-Proof-reading for the
    authors

-AJA Club (in English)
-AJA Club (in Chinese)

 
Abstract

Volume 28, Issue 6 (November 2026) 28, 796–802; 10.4103/aja202614

Dynamic changes of serum albumin-to-globulin ratio predict major adverse cardiovascular events in prostate cancer patients undergoing androgen deprivation therapy

Yi-Hong Zhou1,2 Yan Hiu Athena Lee2 Yu-Xin Tang1 Ying-Bo Dai1 Peter KF Chiu2 Jeremy YC Teoh2 Chi Fai Ng2,

1Department of Urology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China
    2SH Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

Correspondence: Dr. CF Ng (ngcf@surgery.cuhk.edu.hk)

Received: 07 November 2025; Accepted: 15 February 2026; published online: 28 July 2026

Abstract

There are rising concerns regarding the cardiovascular diseases associated with androgen deprivation therapy (ADT) for prostate cancer (PCa). This study aims to investigate the relationship between the dynamic changes (from baseline to 3 months after ADT) of serum albumin-to-globulin ratio (AGR) and major adverse cardiovascular events (MACE) in PCa patients undergoing ADT. Male patients aged >60 years diagnosed with PCa undergoing ADT in Hong Kong (China) between December 01, 1999, and March 31, 2021, were included. AGR values at baseline and after 3 months of ADT initiation were recorded. The incidence of new-onset 4-point MACE (4P-MACE) and composite of adverse cardiovascular events (CACE) were designated as the primary outcomes. The individual components of CACE were designated as the secondary outcomes. A total of 970 patients were analyzed, with age (mean ± standard deviation) of 75.1 ± 7.8 years. The number of patients with increased AGR and decreased AGR were 515 (53.1%) and 455 (46.9%), respectively. Patients with a decreased AGR had significantly higher risks of 4P-MACE, CACE, heart failure (HF), myocardial infarction (MI), and stroke than patients with an increased AGR. No significant difference in the risk of all-cause mortality between the two groups was observed (hazard ratio: 1.049, 95% confidence interval: 0.879–1.253, P = 0.594). Moreover, the change in AGR outperformed the baseline AGR in predicting 4P-MACE, CACE, HF, MI, and stroke. In PCa patients undergoing ADT, dynamic changes of AGR are associated with risks for 4P-MACE, CACE, HF, MI, and stroke.
    
    Keywords: albumin-to-globulin ratio; androgen deprivation therapy; cardiovascular risk; prostate cancer

Full Text | PDF |

 
Browse:  11
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.